NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP
Cardio Diagnostics Holdings, Inc. CDIO
5 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$14,825
▼ 57.5% vs FY2024
EPS · FY25
$-3.71
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-78.6%
Net margin · FY25
-43832.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 14,825.00
Revenue, FY2025 · full 5-year series below
Revenue
Net income
The company lost 43832 cents on every revenue dollar this year.
Per share
USD -3.71
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-78.6%
Return on equity, FY2025
ROE
Operating margin-43737.5%
Net margin-43832.5%
Return on assets-70.7%
Each USD of equity lost 79 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+149.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.8M
total assets, end of FY2025
Total assetsUSD 7.8M
EquityUSD 7.0M
CashUSD 0.00
Current ratio9.79×
Equity funds 90% of total assets.
History
5 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
Revenue $B
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
·
·
·
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−3.71
−9.35
−0.66
−1.51
−0.53
Dividend / sh $
·
·
·
·
·
Payout %
·
·
·
·
·
ROE %
−78.6
−134.0
−230.8
−173.6
−58.1
Shares out B
0.00
0.00
0.02
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
15 of 15
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed